In addition to the decrease in plasma NET levels in lupus mice treated with the TLR7 agonist, a significant decrease in anti-double-stranded DNA and anti-beta-2 glycoprotein autoantibodies was observed. The gene discussed is TLR7; the disease is systemic lupus erythematosus.